Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in
Closed
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverHLN
HealthcareNYQUSD

Haleon plc

$00123456789.0012345678900123456789-3.1%
52w low $8.65$11.28 52w high
Market data · last updated 1d ago
Market data
Market cap
$43.42B
52w range
$8.65 - $11.28
Beta
0.24
Sector
Healthcare
Data quality
100/100
Valuation
P/E ratio
20.1x
fair value estimate
$18.87
Margin of safety
+116.4%
Forward P/E
16.2x
PEG ratio
2.60
Dividend yield
1.98%
Quality & efficiency
Moat score
63/100
Return on equity
10.3%
Profit margin
15.1%
Debt / equity
0.52
Growth & analysts
Revenue growth
+0.6%
Analyst target
$11.65
Target upside
+33.6%
Analysts
5
Run the 10-point checklist before you buy How these numbers are made

About Haleon plc

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Valuation

ValueGrowthProfitHealthIncome54QUALITY
Overall Rating
74
High quality
High quality

Derived from filed metrics · High confidence (100% of the inputs available)

Moat Score63
Fair value estimate
$18.87+116.4% upside

Moat, fair value and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$43.42B
P/E Ratio
20.1
Dividend Yield
1.98%
Revenue Growth
+0.6%
Profit Margin
15.1%
ROE
10.3%
Debt / Equity
0.52
Beta
0.24

Statistics

Similar Stocks · Healthcare

Latest News · HLN